ABL Bio's gastric cancer drug Givastomig shrinks tumors by 79%, advancing phase 3 preparations
Predicted impact: Medium
Same Givastomig 79% tumor shrinkage data already reported; phase 3 prep is incremental.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.